ImClone

(redirected from ImClone Systems)
Also found in: Medical, Wikipedia.

ImClone

A former publicly-traded company specializing in biotechnology, particularly the development of drugs treating cancer. It is known for the insider trading scandal involving its CEO, Sam Waksal, and television personality Martha Stewart. Both served time in federal prison for attempting (Waksal) or conducting (Stewart) insider trading. Since November 2008, ImClone has been a wholly-owned subsidiary of Eli Lilly and Company. Prior to its acquisition, ImClone was traded on NASDAQ.
Mentioned in ?
References in periodicals archive ?
ImClone Systems Incorporated (NASDAQ: IMCL) and UCB have entered into a worldwide strategic partnership for the development and commercialization of CDP-791, a novel, investigational antibody targeting the vascular endothelial growth factor receptor-2 (VEGFR-2) that is currently being developed by UCB.
one of New Jersey's fastest growing general contracting firms, has recently completed a high-end renovation project on behalf of ImClone Systems Incorporated at 33 Chubb Way in Branchburg, N.
Company analysis includes a history of ImClone Systems, a business segment analysis of the segments ImClone Systems operates through, a look at the organization structure of the company, a geographical operating segments analysis, an analysis of the company's major competitors.
NEW YORK -- ImClone Systems Incorporated (NASDAQ: IMCL) announced today that the Company is scheduled to present at the Goldman Sachs 28th Annual Global Health Care Conference in Dana Point, CA on June 13, 2007 from 3:20 PM to 3:50 PM Pacific Time (6:20 PM to 6:50 PM Eastern Time).
NEW YORK -- ImClone Systems Incorporated (NASDAQ: IMCL) announced that the Company is scheduled to present at the Bear Stearns 3rd Annual Biotech Confab in Boston, MA on June 7, 2007 from 4:50 PM to 5:15 PM Eastern Time.
NEW YORK -- ImClone Systems Incorporated (NASDAQ: IMCL) announced today that the Company is scheduled to present at the Citigroup 2007 Healthcare Conference in New York, NY on Thursday, May 24, 2007 from 12:00 PM to 12:25 PM Eastern Time.
NEW YORK -- ImClone Systems Incorporated (NASDAQ: IMCL) announced that the Company is scheduled to present at the Morgan Stanley Global Healthcare Unplugged Conference from 11:00 AM to 11:40 AM Eastern Time today.
NEW YORK -- ImClone Systems Incorporated (NASDAQ: IMCL) announced today that the Company is scheduled to present at The Lehman Brothers 10th Annual Global Healthcare Conference in Miami, Florida on Wednesday, March 21, 2007 from 10:45 AM to 11:10 AM Eastern Time.
NEW YORK -- ImClone Systems Incorporated (NASDAQ: IMCL) announced today that the Company is scheduled to present at The Cowen and Company Twenty Seventh Annual Health Care Conference on Tuesday, March 13, 2007 from 8:00 AM to 8:35 AM Eastern Time.
NEW YORK -- ImClone Systems Incorporated (NASDAQ: IMCL) announced today that it has opted-out of its development agreement with UCB S.
NEW YORK -- ImClone Systems Incorporated (NASDAQ: IMCL) announced today that the Company is scheduled to present at The Merrill Lynch Eighteenth Annual Global Pharmaceutical, Biotechnology and Medial Device Conference on Tuesday, February 6, 2007 from 2:20 PM to 3:00 PM Eastern Time.
NEW YORK -- ImClone Systems Incorporated (NASDAQ: IMCL) today announced that it expects to disclose the result of a Phase III study of ERBITUX([R]) (cetuximab) plus FOLFIRI (an irinotecan-based chemotherapy) in patients with previously untreated metastatic colorectal cancer, before the end of the week of January 8, 2007.